Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Naxozol is a combination product of naproxen, a non-steroidal anti-inflammatory drug (NSAID)
and esomeprazole, a proton pump inhibitor which is designed to improve symptoms and reduce
risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers in
the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The
purpose of this study is to investigate whether naxozol protects the gastrointestinal tract
effectively compared to celecoxib, a COX-2 inhibitor.